clene-logo@2x.png
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
May 08, 2024 08:00 ET | Clene Inc.
Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from...
clene-logo@2x.png
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
April 16, 2024 16:01 ET | Clene Inc.
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original...
clene-logo@2x.png
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
March 15, 2024 08:00 ET | Clene Inc.
Proprietary catalytic gold nanocrystals comprising Clene’s investigational drug CNM-Au8® develop a protein corona upon exposure to human blood plasma comprised of proteins that promote blood-brain...
clene-logo@2x.png
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
March 13, 2024 08:00 ET | Clene Inc.
Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label...
clene-logo@2x.png
Clene to Present at the 36th Annual ROTH Conference
March 07, 2024 08:00 ET | Clene Inc.
SALT LAKE CITY, March 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
clene-logo@2x.png
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
February 29, 2024 08:00 ET | Clene Inc.
Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contrast letter acuity (LCLA), an assessment of visual function in people living...
clene-logo@2x.png
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
February 22, 2024 08:00 ET | Clene Inc.
Two “Compassionate Use” Expanded Access Programs (EAPs) provided access to treatment with CNM-Au8 to more than 250 people living with amyotrophic lateral sclerosis (ALS).A significant survival benefit...
clene-logo@2x.png
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
January 08, 2024 07:00 ET | Clene Inc.
Long-term CNM-Au8 treatment demonstrated improvement of vision as measured by low contrast visual acuity (LCLA), an assessment of visual function in people living with multiple sclerosis (MS), through...
clene-logo@2x.png
Clene Provides Update on ALS Clinical Development Meeting With FDA
December 21, 2023 07:00 ET | Clene Inc.
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
clene-logo@2x.png
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
December 21, 2023 07:00 ET | Clene Inc.
CNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023)60% decreased risk of...